Literature DB >> 19231764

Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease.

Allan J Collins1, Joseph A Vassalotti, Changchun Wang, Suying Li, David T Gilbertson, Jiannong Liu, Robert N Foley, Shu-Cheng Chen, Thomas J Arneson.   

Abstract

To address the highly complex interrelated nature of chronic kidney disease (CKD) and diabetes, hypertension, and cardiovascular disease, we examined CKD prevalence by the predictive effect of demographic factors, comorbid conditions, and CKD risk factors by using National Health and Nutrition Examination Survey (NHANES) 1999-2004 data. NHANES is a nationally representative cross-sectional series of surveys with a complex stratified multistage sampling design. NHANES 1999-2004 participants (n = 15,332; age > or = 20 years) were interviewed in their homes and asked to participate in standardized medical examinations in mobile centers and provide samples for laboratory tests. Weighted logistic regression modeling was used to assess the importance of individual CKD risk factors. Multiple logistic regressions were performed on patient cohorts, with increasing levels of CKD severity defined by means of estimated glomerular filtration rate. A branching diagram was constructed to address the distribution of CKD grouped by diabetes, hypertension, and cardiovascular disease status. CKD prevalence increases with age (39.2% for age > or = 60 years). For ages 20 to 59 years, CKD prevalence was greater for participants with diabetes (33.8%) than for those without diabetes (8.2%) and for participants with both diabetes and hypertension (43%) than for diabetic participants without hypertension (25.5%) or nondiabetic participants with hypertension (15.2%). The prevalence was 6.8% for nondiabetic participants without hypertension. Effects of cardiovascular disease are less dramatic when hypertension and diabetes are considered. A CKD screening approach targeting individuals 60 years and older or those with diabetes or hypertension likely would be useful from a public health standpoint.

Entities:  

Mesh:

Year:  2009        PMID: 19231764     DOI: 10.1053/j.ajkd.2008.07.057

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  25 in total

1.  Cost-effectiveness of chronic kidney disease mass screening test in Japan.

Authors:  Masahide Kondo; Kunihiro Yamagata; Shu-ling Hoshi; Chie Saito; Koichi Asahi; Toshiki Moriyama; Kazuhiko Tsuruya; Hideaki Yoshida; Kunitoshi Iseki; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-12-14       Impact factor: 2.801

Review 2.  Approach to the detection and management of chronic kidney disease: What primary care providers need to know.

Authors:  Allan K Grill; Scott Brimble
Journal:  Can Fam Physician       Date:  2018-10       Impact factor: 3.275

3.  Routine screening for CKD should be done in asymptomatic adults... selectively.

Authors:  Jeffrey S Berns
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-18       Impact factor: 8.237

4.  Identifying High-Risk Individuals for Chronic Kidney Disease: Results of the CHERISH Community Demonstration Project.

Authors:  Nilka Ríos Burrows; Joseph A Vassalotti; Sharon H Saydah; Rebecca Stewart; Monica Gannon; Shu-Cheng Chen; Suying Li; Sarah Pederson; Allan J Collins; Desmond E Williams
Journal:  Am J Nephrol       Date:  2018-11-23       Impact factor: 3.754

5.  Development and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Paul Muntner; Mark Woodward; April P Carson; Suzanne E Judd; Emily B Levitan; Devin M Mann; William McClellan; David G Warnock
Journal:  Am J Kidney Dis       Date:  2011-05-26       Impact factor: 8.860

6.  Endothelial Epas1 Deficiency Is Sufficient To Promote Parietal Epithelial Cell Activation and FSGS in Experimental Hypertension.

Authors:  Yosu Luque; Olivia Lenoir; Philippe Bonnin; Lise Hardy; Anna Chipont; Sandrine Placier; Sophie Vandermeersch; Yi-Chun Xu-Dubois; Blaise Robin; Hélène Lazareth; Michèle Souyri; Léa Guyonnet; Véronique Baudrie; Eric Camerer; Eric Rondeau; Laurent Mesnard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2017-09-19       Impact factor: 10.121

7.  Estimated Glomerular Filtration Rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice.

Authors:  Waad-Allah S Mula-Abed; Khalid Al Rasadi; Dawood Al-Riyami
Journal:  Oman Med J       Date:  2012-03

Review 8.  Aging, diabetes, and the public health system in the United States.

Authors:  Carl J Caspersen; G Darlene Thomas; Letia A Boseman; Gloria L A Beckles; Ann L Albright
Journal:  Am J Public Health       Date:  2012-06-14       Impact factor: 9.308

9.  Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.

Authors:  Raymond R Townsend; Alan D Forker; Vaishali Bhosekar; Anthony Yadao; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-11       Impact factor: 3.738

10.  Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital.

Authors:  Giorgio Gentile; Maurizio Postorino; Raymond D Mooring; Luigi De Angelis; Valeria Maria Manfreda; Fabrizio Ruffini; Manuela Pioppo; Giuseppe Quintaliani
Journal:  BMC Nephrol       Date:  2009-09-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.